Compare INKT & MLSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INKT | MLSS |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 42.6M |
| IPO Year | 2021 | 1996 |
| Metric | INKT | MLSS |
|---|---|---|
| Price | $11.09 | $0.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $1.00 |
| AVG Volume (30 Days) | 7.0K | ★ 182.6K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,973,982.00 |
| Revenue This Year | N/A | $12.64 |
| Revenue Next Year | N/A | $8.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.99 |
| 52 Week Low | $8.48 | $0.22 |
| 52 Week High | $16.80 | $0.65 |
| Indicator | INKT | MLSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 52.18 |
| Support Level | $10.76 | $0.25 |
| Resistance Level | $12.20 | $0.48 |
| Average True Range (ATR) | 0.66 | 0.04 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 18.31 | 28.72 |
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.